Drug Profile
Research programme: human monoclonal antibodies - Medarex/Mitsubishi Tanabe Pharma
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Medarex; Mitsubishi Pharma Corporation
- Developer Medarex; Mitsubishi Tanabe Pharma Corporation
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 26 May 2010 Preclinical development is ongoing in USA